The ongoing phase I clinical trial PALVEN (NCT03900884) is evaluating the safety and efficacy of AI plus CDK4/6i combined with venetoclax as a first-line treatment in metastatic HR+/HER2− BC patients with BCL2 overexpression. This evidence concerns the gene BCL2 and breast cancer.